{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"US_2017_0247693_A1","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"018-562-602-782-90X","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":10791,"type":"PATENT","title":"The Hebrew University of Jerusalem - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":7593,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8259,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: \"hebrew univ* jerusalem\"; \"hebrew univ* jerus*\"
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1457
Search Applicants and Owners separately: \"hebrew univ* jerusalem\"; \"hebrew univ* jerus*\"
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1457
a. contacting said cell with a replication competent retrovirus (RCR) comprising one or more antisense molecules that target at least one hypoxia-inducible gene selected from the group consisting of: HIF-1 and CREB, and\n
b. exposing said cell to an anti-cancer therapy,\n
thereby inducing cell death in a proliferating cell."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein said RCR comprises an antisense molecule that targets at least two hypoxia-inducible genes selected from the group consisting of: HIF-1, HIF-2 and CREB."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein said RCR comprises an antisense molecule that targets HIF-1, HIF-2 and CREB."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein said RCR comprises a nucleic acid sequence selected from the group consisting of: GAGAGAGGTCCGTCTAATG (SEQ ID NO: 14), CTAACTGGACACAGTGTGTTT (SEQ ID NO: 15), and CTAACTGGACACAGTGTGTTTAATATATGAAAACACACTGTGTCCAGTTAGTAAGT CGACTCGCTTATTAAAGTATTCTGATCCGATTATAAAGGATCAGAATACTTTAATA AGAATGGCGCGTCTTCGAGAGAGGTCCGTCTAATG (SEQ ID NO: 16)."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein said retrovirus is a Murine Leukaemia virus (MuLV)."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein said anti-cancer therapy comprises a therapy selected from the group consisting of: radiation therapy, chemotherapy, immunotherapy, and any combination thereof."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 6, wherein said anti-cancer therapy is a chemotherapy comprising administering a chemotherapeutic agent selected from the group consisting of: Doxorubicin and Dacarbazine."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein said proliferating cell is a cancerous cell."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["A method of treating, or ameliorating cancer in a subject in need thereof, the method comprising:\n
a. administering to said subject a replication competent retrovirus (RCR) comprising one or more antisense molecules that target at least one hypoxia-inducible gene selected from the group consisting of: HIF-1 and CREB, and\n
b. administering to said subject an anti-cancer therapy,\n
thereby treating or ameliorating cancer in a subject in need thereof."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 9, wherein said RCR comprises an antisense molecule that targets at least two hypoxia-inducible genes selected from the group consisting of: HIF-1, HIF-2 and CREB."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 9, wherein said RCR comprises a nucleic acid sequence selected from the group consisting of: GAGAGAGGTCCGTCTAATG (SEQ ID NO: 14), CTAACTGGACACAGTGTGTTT (SEQ ID NO: 15), and CTAACTGGACACAGTGTGTTTAATATATGAAAACACACTGTGTCCAGTTAGTAAGT CGACTCGCTTATTAAAGTATTCTGATCCGATTATAAAGGATCAGAATACTTTAATA AGAATGGCGCGTCTTCGAGAGAGGTCCGTCTAATG (SEQ ID NO: 16)."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 9, wherein said retrovirus is a Murine Leukaemia virus (MuLV)."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 9, wherein said anti-cancer therapy comprises a therapy selected from the group consisting of: radiation therapy, chemotherapy, immunotherapy, and any combination thereof."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 13, wherein said chemotherapy comprises a chemotherapeutic agent selected from the group consisting of: Doxorubicin and Dacarbazine."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 9, wherein said cancer is a solid tumour."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 9, wherein said cancer is selected from the group consisting of: hepatoma, melanoma, liver cancer, epithelial cancer, carcinoma and hepatocellular carcinoma."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 9, wherein said cancer is selected from uveal melanoma and hepatocellular carcinoma (HCC)."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 9, wherein administering said RCR is prior to, or together with, administering said anti-cancer therapy."],"number":18,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 9, wherein administering said RCR potentiates at least one anti-cancer effect of said anti-cancer therapy."],"number":19,"annotation":false,"claim":true,"title":false},{"lines":["A kit comprising at least one agents selected from the group consisting of:\n
a. a replication competent retrovirus (RCR) comprising at least one antisense molecule that targets a hypoxia-inducible gene selected from the group consisting of: HIF-1 and CREB, the RCR being adapted or identified for co-administration with an anti-cancer agent; and\n
b. an anti-cancer agent, adapted or identified for co-administration with an RCR."],"number":20,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}